Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Pays $98M for Yokogawa s Stake in Gas Chromatography Joint Venture

NEW YORK, Jan. 31 (GenomeWeb News) - Agilent Technologies and Yokogawa Electric said today that their joint venture, Yokogawa Analytical Systems, will become a wholly owned Agilent subsidiary effective Feb. 1.


Yokogawa will receive around $106 million from the transaction, including $98 million from Agilent for its 49-percent share in the joint venture and $7.5 million in dividends from Yokogawa Analytical Systems.


The companies formed the joint venture in 1992 to develop and market the ICP/MS, an analytical system used in gas chromatography.


At the time, Agilent transferred its sales and support of advanced laboratory analytical systems to Yokogawa Analytical Systems, while Yokogawa Electric transferred all of its laboratory business, including equipment under development, to the joint venture.


The joint venture had sales of more than $160 million in fiscal 2005, the companies said.


Agilent and Yokogawa said in a statement that the joint venture had "achieved its original objectives set 13 years ago," and that Agilent decided to make Yokogawa Analytical Systems a wholly owned subsidiary in order to expand the market presence for its products and services in Japan.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.